Table 2.
Reporting of sexual activity, sexual dissatisfaction, and BC decreased their sexual activity frequency in relation to general health and cancer‐related conditions
| Total | Sexual activity | Sexual dissatisfaction | BC decreased their sexual activity frequency | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| N (%) | P a | AOR | N (%) | P a | AOR | N (%) | P a | AOR | ||
| General Health | ||||||||||
| BMI (kg/m2) | ||||||||||
| Underweight (<18.5) | 9 (2.6%) | 1 (11.1) | Ref | 4 (44.4) | Ref | 7 (77.8) | ||||
| Normal weight (18.5‐24.9) | 242 (71.0%) | 55 (22.7) | 3.08 (0.35, 27.31) | 49 (20.3) | 0.32 (0.07, 1.31) | 132 (54.6) | 0.41 (0.08, 2.06) | |||
| Overweight (25.0‐29.9) | 79 (23.2%) | 24 (30.4) | 4.72 (0.51, 43.95) | 25 (31.7) | 0.63 (0.14, 2.76) | 55 (69.6) | 0.80 (0.15, 4.26) | |||
| Obesity (≥30) | 11 (3.3%) | 3 (27.3) | .421 | 2.83 (0.22, 37.14) | 3 (27.3) | .087 | 0.47 (0.07, 3.23) | 7 (63.6) | .07 | 0.56 (0.07, 4.21) |
| Menopausal statusb | ||||||||||
| Regular menstrual | 10 (3.7%) | 4 (40.0) | Ref | 0 (0) | Ref | 8 (66.7) | Ref | |||
| Irregular menstrual | 20 (7.4%) | 10 (50.0) | 0.89 (0.17, 4.65) | 6 (30) | — | 16 (76.2) | 1.20 (0.20, 7.30) | |||
| Postmenopausal | 242 (89.0%) | 56 (23.1) | .018 | 0.54 (0.14, 2.16) | 61 (25.2) | .164 | — | 177 (57.5) | .207 | 0.59 (0.14, 2.46) |
| Self‐reported general health status | ||||||||||
| Bad/very bad | 32 (9.4%) | 4 (12.5) | Ref | 13 (40.6) | Ref | 21 (65.6) | Ref | |||
| Fair | 206 (60.6%) | 42 (20.3) | 1.68 (0.54, 5.16) | 45 (21.7) | 0.39 (0.17, 0.87) | 125 (60.4) | 0.75 (0.34, 1.68) | |||
| Good/very good | 102 (30.0%) | 37 (36.3) | .002 | 3.28 (1.03, 10.42) | 23 (22.6) | .061 | 0.34 (0.17, 0.83) | 55 (53.9) | .400 | 0.51 (0.21, 1.19) |
| Cancer‐related characteristics | ||||||||||
| Stagec | ||||||||||
| 0‐I | 115 (37.8%) | 24 (20.9) | Ref | 25 (21.7) | Ref | 64 (55.7) | Ref | |||
| II | 140 (46.1%) | 43 (30.7) | 1.54 (0.84, 2.82) | 39 (27.9) | 1.39 (0.77, 2.52) | 90 (64.3) | 1.32 (0.79, 2.21) | |||
| III‐IV | 49 (16.1%) | 9 (18.4) | .098 | 0.78 (0.32, 1.90) | 9 (18.4) | .314 | 0.78 (0.33, 1.86) | 27 (55.1) | .297 | 0.93 (0.47, 1.84) |
| Time since diagnosis (y)c | ||||||||||
| <3 | 115 (33.7%) | 30 (26.1) | 25 (21.7) | 72 (62.6) | ||||||
| ~3 | 132 (38.7%) | 30 (22.7) | 0.79 (0.43, 1.47) | 41 (31.1) | 1.71 (0.94, 3.09) | 76 (57.6) | 0.88 (0.52, 1.49) | |||
| ≥5 | 94 (27.6%) | 23 (24.5) | .828 | 1.19 (0.61, 2.23) | 15 (16.0) | .026 | 0.67 (0.32, 1.40) | 53 (56.4) | .608 | 0.85 (0.48, 1.52) |
| Surgery type | ||||||||||
| Lumpectomy | 39 (11.4%) | 14 (35.9) | Ref | 7 (18.0) | Ref | 20 (51.3) | Ref | |||
| Mastectomy | 302 (88.6%) | 69 (22.9) | .074 | 0.51 (0.24, 1.11) | 74 (24.5) | .365 | 1.89 (0.78, 4.57) | 181 (59.9) | .301 | 1.49 (0.75, 2.94) |
| Breast reconstructione | ||||||||||
| Yes | 8 (2.7%) | 4 (50.0) | Ref | 2 (25.0) | Ref | 5 (62.5) | Ref | |||
| No | 294 (97.4%) | 65 (22.2) | .081 | 0.38 (0.09, 1.70) | 72 (24.9) | .316 | 0.98 (0.19, 5.20) | 176 (59.9) | .999 | 1.06 (0.25, 4.60) |
| Radiotherapy | ||||||||||
| No | 225 (66.0%) | 55 (24.4) | Ref | 56 (24.9) | Ref | 129 (57.3) | Ref | |||
| Yes | 116 (34.0%) | 28 (24.1) | .95 | 0.81 (0.46, 1.40) | 25 (21.6) | .492 | 0.77 (0.44, 1.34) | 72 (62.1) | .399 | 1.14 (0.72, 1.83) |
| Chemotherapy | ||||||||||
| No | 51 (15.0%) | 11 (21.6) | Ref | 12 (23.5) | Ref | 23 (45.1) | Ref | |||
| Yes | 290 (85.0%) | 72 (24.8) | .617 | 1.09 (0.52, 2.32) | 69 (23.8) | .967 | 1.08 (0.53, 2.22) | 178 (61.4) | .029 | 1.88 (1.02, 3.48) |
| Hormonal therapy | ||||||||||
| Never | 125 (36.7%) | 25 (20) | Ref | 32 (25.6) | Ref | 72 (57.6) | Ref | |||
| Ever | 33 (9.7%) | 9 (27.3) | 1.68 (0.66, 4.32) | 7 (21.2) | 1.00 (0.38, 2.65) | 17 (51.5) | 0.82 (0.37, 1.82) | |||
| Current | 183 (53.6%) | 49 (26.8) | .364 | 1.44 (0.81, 2.54) | 42 (23.0) | .811 | 0.81 (0.47, 1.39) | 112 (61.2) | .54 | 1.13 (0.70, 1.81) |
| Recurrance | ||||||||||
| No | 331 (97.1%) | 82 (24.8) | Ref | 80 (24.2) | Ref | 196 (59.2) | Ref | |||
| Yes | 10 (2.9%) | 1 (10.0) | .284 | 0.33 (0.04, 2.79) | 1 (10.0) | .299 | 0.36 (0.04, 3.03) | 5 (50.0) | .56 | 0.78 (0.21, 2.84) |
| Metastasis | ||||||||||
| No | 323 (94.7%) | 79 (24.5) | Ref | 76 (23.5) | Ref | 188 (58.2) | Ref | |||
| Yes | 18 (5.3%) | 4 (22.2) | .83 | 0.71 (0.21, 2.35) | 5 (27.8) | .68 | 1.24 (0.41, 3.77) | 13 (72.2) | .239 | 2.15 (0.72, 6.42) |
All models were adjusted for age, marital status, self‐reported general health status, and time since cancer diagnosis.
Bold face P < .05.
Abbreviations: AOR, adjusted odds ratio; BC, breast cancer.
Chi‐square test or Fisher's exact test.
Analysis restricted to individuals aged 45‐64 y (n = 272). BC deemed to be postmenopausal when they had not menstruated in the past year.
Cancer stage was unknown for 37 subjects. Stage 0‐Ⅰ groups include 10 subjects with stage 0 and 105 subjects with stage Ⅰ. Stage Ⅲ‐Ⅳ groups include 44 subjects with stage Ⅲ and 5 subjects with stage Ⅳ.
Subjucts who received their cancer diagnosis <3 y (n = 115) includes 2 subjects with cancer diagnosis <1 y and 113 subjects with cancer diagnosis 1‐3 y.
Analysis restricted to individuals with mastectomy (n = 302).